New compound shows promise for perio disease

Aug 11, 2009

A proprietary compound called 1-tetradecanol complex (1-TDC) has been shown to be effective in arresting the progression of periodontal disease, according to a study published in the July issue of the Journal of Periodontology (Vol. 80:7, pp. 1103-1113), according to Imagenetix, the company that developed 1-TDC.

In the study, the compound was applied to the gum line using a rabbit periodontitis model developed by Boston University investigators. The study results showed that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration in tissue and bone health compared to the placebo group.

"The results of this experiment are very exciting and demonstrate the great promise that 1-TDC offers in the treatment of periodontal disease," said lead researcher Hatice Hasturk, D.D.S., Ph.D., an assistant professor in the department of periodontology and oral biology at Boston University, in a press release. "These findings clearly demonstrate that 1-TDC reverses, at least in part, the damage associated with experimental periodontitis. We look forward to continuing our work with Imagenetix as they move toward the path of a new drug application and progressive drug development with the FDA."

Imagenetix now has two published animal studies showing clear evidence of 1-TDC's efficacy, noted Imagenetix President William Spencer in the release. "We continue to position our 1-TDC for a phase I trial with the FDA. In addition, we anticipate receiving news shortly on our patent associated with this compound. We also have contracted with an internationally respected clinical research organization to provide Imagenetix specific time lines to achieve drug approval from the FDA."